BioGaia acquires remaining 50 per cent of TwoPac AB
BioGaia has previously owned 50 per cent of TwoPac AB and the remaining shares have been held by TwoPac’s management. BioGaia has today signed an agreement to acquire the remaining 50 per cent. The total purchase consideration amounts to SEK 30 million and the change of ownership will take place on 1 July 2013.
TwoPac AB was formed in 2002 to manufacture and develop packaging solutions for probiotics. At present the company primarily produces probiotic drops, but also manufactures straws on behalf of BioGaia. The company’s revenue consists entirely of sales to BioGaia. In 2012 the company completed a new factory in Eslöv, Sweden, that was financed mainly with loans from BioGaia. TwoPac is consolidated in the Group since 1 January 2011.
BioGaia has today signed an agreement to acquire the remaining 50 per cent of the shares and TwoPac AB will thus become a wholly owned subsidiary of BioGaia AB. The motives is to gain full control over part of the company’s product manufacturing, but above all to join forces with TwoPac in effective development of new products that can be manufactured at a reasonable cost.
TwoPac is profitable. If the company had been acquired at January 1, 2012, BioGaia’s earnings per share would have increased from SEK 3.52 to SEK 3.70 (excluding licence revenue from Nestlé).
Per Hjalmarsson, the current President of TwoPac, will continue to manage the company.
“The most important aspect of the acquisition is that it will give us unlimited access to TwoPac’s product development capacity and expertise in building customised machinery,” says Peter Rothschild, President of BioGaia.
Latest press releases from BioGaia
2013-05-30 BioGaia signs agreement with Nestlé for new category of products
2013-05-13 BioGaia signs exclusive distribution agreement in China
2013-05-07 BioGaia signs exclusive distribution agreement in South Korea
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 18 June 2013, 2:00 p.m CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com